600351 亚宝药业
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,663,165-2.67%2,240,0642,686,0382,909,7652,718,135
减:营业总成本1,338,449-5.88%1,910,0002,391,5422,620,7412,539,492
    其中:营业成本757,416-7.39%1,063,7891,297,8531,226,3421,199,376
               财务费用(1,800)-28.40%(3,176)(814)3,22310,829
               资产减值损失(3,480)-94.76%(83,580)(42,163)(93,749)(68,059)
公允价值变动收益(20,161)-1,957.28%19,004(2,847)(2,582)(3,541)
投资收益2,80379.98%74,039(188)(2,764)(631)
    其中:对联营企业和合营企业的投资收益844-376.00%9,107(321)(412)(375)
营业利润325,08828.36%370,839299,953226,335123,548
利润总额322,87327.43%374,458292,108218,981125,647
减:所得税费用66,12720.51%74,55868,19339,06821,043
净利润256,74629.35%299,899223,916179,914104,604
减:非控股权益150-100.90%(20,114)(18,773)(19,672)(51)
股东净利润256,59619.29%320,013242,688199,586104,655

市场价值指针
每股收益 (元) *0.37120.94%0.4600.3400.2600.140
每股派息 (元) *0.2000.00%0.3500.3000.1500.050
每股净资产 (元) *3.984-0.26%4.1684.0183.8653.857
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容